Posters

    High Content Screening (HCS) approach to characterize phenotypic changes occurring during long-term treatment of human bronchial epithelial cells with cigarette smoke total particulate matter

    Marescotti, D.; van der Toorn, M.; Laurent, A.; Luettich, K.; Frentzel, S.; Peitsch, M.; Hoeng, J.

    Conference date
    Sep 7, 2016
    Conference name
    EUROTOX 2016
    Link to more information
    Topic
    Summary

    No abstract available.

    Related Publications

    Barriers to stop smoking (BASS): Results and insights from four years of empirical research in Germany

    Perception and Behavior

    Unlocking a decade of tobacco heating system post-market surveillance

    Post-Market Studies and Surveillance Study

    Reasons for oral nicotine product use among adults who smoke or use smoke-free products in Germany - Results from the Barrier to Stopping smoking (BASS) survey

    Perception and Behavior

    Misunderstanding nicotine delivery: Discussion on nicotine pouches

    Nicotine

    AeroSolved: Wall Boundary Conditions for Liquid Multispecies Aerosol Deposition at Transient and High-Humidity Flows

    Aerosol Physics

    Bridging Approaches to Facilitate Innovation: Building an Approach for Heated Tobacco Products from Case Studies in the Food and Drug Domains a Comparative Review

    Aerosol Chemistry;Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.